Luxin Venture Capital Group Co.,Ltd.

Luxin Venture Capital Group (鲁信创投) shows up in elsewhere's corpus mainly through its portfolio activity rather than any dedicated profile. The clearest self-description comes from its own deputy general manager Qiu Fang, who called it a state-controlled professional venture capital institution whose stated mandate is to back domestic research platforms and the commercialization of homegrown instruments and equipment, putting "high-level technological self-reliance" first . Consistent with that, in early 2024 it led a nearly RMB 100 million Series A in Aoxu Technology (ACX Instruments), a digital microfluidics platform, with Qiming Venture Partners, Linear Capital and Cowin Capital also increasing their positions . Its other appearances are mostly as a follow-on investor in healthcare: it joined Sibionics' RMB 500M+ C++ round in January 2022 as an existing shareholder , and as of April 2026 was among the co-investors in OriCell Therapeutics' $110 million Pre-IPO round .

Beyond these deal records — founding date, AUM, ownership structure — elsewhere's corpus does not cover them, so a fuller profile isn't available here.